Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)

By Keith Speights - May 2, 2018 at 5:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These two big pharma stocks have a lot in common. But only one is the better choice right now.

This big drugmaker faces challenges in the future for its top-selling product, a highly successful immunology drug. But it also has one of the fastest-growing cancer drugs in the world in its lineup and a promising pipeline. In addition, the company pays a solid dividend that many investors love.

What company am I talking about? Johnson & Johnson (JNJ 0.01%), of course. But I'm also referring to AbbVie (ABBV -0.78%). Each of the statements applies to both of these big pharma companies.

AbbVie has been the better stock over the last few years, but which is the better pick for long-term investors? Here's how AbbVie and J&J compare.

Woman holding palms facing upward in front of chalkboard drawing of scales

Image source: Getty Images.

Growth prospects

AbbVie appears to have the stronger growth prospects over the next several years. The company should enjoy a few more years of growth for its top-selling drug Humira. Although Humira will see challenges from biosimilars in Europe later in 2018, it should keep biosimilar rivals at bay in the more lucrative U.S. market until 2023.

Meanwhile, AbbVie recently announced a monster first quarter, with tremendous sales growth for cancer drug Imbruvica. The biggest story in Q1, though, was the big sales jump for new hepatitis C virus (HCV) drug Mavyret. 

AbbVie also has a pipeline loaded with potential winners. Upadacitinib and risankizumab could be worthy heirs to Humira in the immunology arena. The company hopes to win FDA approval for elagolix in managing endometriosis within the next couple of months. AbbVie also has several oncology programs that could pay off, despite a significant setback in March for experimental lung cancer drug Rova-T.

Johnson & Johnson has a more immediate challenge for its top-selling drug Remicade. Biosimilar competition already is taking a toll on sales for the immunology drug. Sales also are falling for other drugs in J&J's current lineup, including Concerta, Invokana, and Risperdal Consta.

However, J&J does have several growth drivers. Immunology drugs Simponi and Stelara continue to enjoy strong momentum. Sales for J&J's cancer drugs Darzalex, Imbruvica (which it co-markets with AbbVie), and Zytiga are growing briskly. Its pulmonary hypertension franchise, acquired from Actelion, is also contributing to the company's overall growth. J&J also recently won Food and Drug Admnistration (FDA) approval for promising prostate cancer drug Erleada.

J&J's pipeline includes several late-stage programs seeking additional indications for already-approved drugs such as Xarelto, Invokana, Simponi, Stelara, Imbruvica, and Tremfya. The company also has some new drugs that could be on the way, notably including esketamine for treating depression.

Overall, though, Johnson & Johnson likely won't grow as quickly as AbbVie. One reason is that much of the company's growth in the first quarter came from acquisitions, especially the buyout of Actelion. In addition, J&J's growth is held back somewhat by its consumer healthcare and medical-device segments. 


Johnson & Johnson claims one of the best track records for dividends, with 56 consecutive years of dividend increases. The company's dividend currently yields 2.57%.

AbbVie's dividend history isn't too shabby, either. It's increased its dividend by 140% since being spun off from Abbott Labs in 2013. AbbVie's dividend yield currently stands at 4.2%.


Probably the best way to compare these two companies' valuations is to look ahead. Johnson & Johnson stock trades at a little under 15 times expected earnings. That's relatively inexpensive considering the stability of the company.

AbbVie, however, looks like a bargain. The stock trades at only 11 times expected earnings. Factoring in its growth prospects makes AbbVie stock look even more attractive.

Better buy

I have long believed that Johnson & Johnson is one of the premier blue-chip stocks on the market and still hold that view. Because of its wide range of businesses, J&J gives investors exposure to multiple areas within the healthcare sector by buying only one stock. So is J&J the better buy? I don't think so.

As much as I like Johnson & Johnson, I think there's a more compelling case for AbbVie right now. The stock is oversold, in my view, because of the Rova-T clinical failure mentioned earlier. AbbVie has better growth prospects than J&J and claims a more attractive dividend yield. While the company can't afford another major pipeline setback, I like the overall value proposition for AbbVie right now. 

Keith Speights owns shares of AbbVie. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has the following options: short May 2018 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$167.58 (0.01%) $0.01
AbbVie Inc. Stock Quote
AbbVie Inc.
$141.44 (-0.78%) $-1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.